Announcements Trials
Browse Landscape

Status

Recruiting 2Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 8Observational 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Pregnancy Complications 1Leiomyoma 1Endometriosis 1

Interventions

Surveys and Questionnaires 39Blood Specimen Collection 23Specimen Handling 14Radiotherapy 12Surgical Procedures, Operative 10Magnetic Resonance Spectroscopy 10Interviews as Topic 10Observation 9Drug Therapy 9Data Collection 8Immunotherapy 7Watchful Waiting 5Tomography, X-Ray Computed 5Radiosurgery 5Nivolumab 5Mental Status and Dementia Tests 5Mastectomy, Segmental 5Immune Checkpoint Inhibitors 5Biopsy 5ribociclib 4palbociclib 4lorlatinib 4Therapeutics 4Positron Emission Tomography Computed Tomography 4Magnetic Resonance Imaging 4Ipilimumab 4High-Throughput Nucleotide Sequencing 4Hepatectomy 4Echocardiography 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Observational × relugolix × Clear all
NCT05467176 2026-04-08

OPTYX

Sumitomo Pharma America, Inc.

Active not recruiting
999 enrolled
Genitourinary

Prostatic Neoplasms

NCT05739136 2025-08-01

MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy

Sumitomo Pharma Switzerland GmbH

Active not recruiting
530 enrolled

Endometriosis, Leiomyoma, Pregnancy Complications

Data powered by HemOnc (CC BY 4.0) Colophon ⚡